Efg Asset Management (North America) Corp. Vaxcyte, Inc. Transaction History
Efg Asset Management (North America) Corp.
- $568 Million
- Q1 2024
A detailed history of Efg Asset Management (North America) Corp. transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Efg Asset Management (North America) Corp. holds 19,425 shares of PCVX stock, worth $1.48 Million. This represents 0.23% of its overall portfolio holdings.
Number of Shares
19,425Holding current value
$1.48 Million% of portfolio
0.23%Shares
1 transactions
Others Institutions Holding PCVX
# of Institutions
268Shares Held
97.1MCall Options Held
202KPut Options Held
147K-
Vanguard Group Inc Valley Forge, PA9.74MShares$743 Million0.01% of portfolio
-
Black Rock Inc. New York, NY9.51MShares$725 Million0.02% of portfolio
-
Janus Henderson Group PLC London, X07.67MShares$585 Million0.29% of portfolio
-
Wellington Management Group LLP Boston, MA4.92MShares$375 Million0.06% of portfolio
-
Capital Research Global Investors Los Angeles, CA4.14MShares$316 Million0.07% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $4.52B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...